

Appendix 4E

Preliminary final report

Name of entity

Bard1 Life Sciences Limited

ABN or equivalent company
reference

58 009 070 384

Six month period ended ('current
period')

30 June 2016

Year ended ('comparative period')

31 December 2015

Results for announcement to the market

\$AUD

Revenues from ordinary activities	Up	N/A	To	0
Loss from ordinary activities after tax attributable to members	Up	2,939%	To	(2,591,093)
Net loss for the period attributable to members	Up	2,939%	To	(2,591,093)
Dividends (distributions)		Amount per security		Franked amount per security
Interim dividend		Nil		- ¢
Final dividend		Nil		- ¢
Previous corresponding period		Nil		- ¢
+Record date for determining entitlements to the dividend, (in the case of a trust, distribution)	N/A			

The above results should be read in conjunction with the notes and commentary contained in this report.

Management Discussion and Analysis

1. Overview

As announced to ASX on 1 December 2015, the Company entered into binding share sale and purchase agreements under which it agreed, subject to shareholder approval and the satisfaction of certain other conditions, to acquire all the issued capital of BARD1AG SA, a Swiss public company limited by shares. BARD1AG has pioneered, through the development of certain proprietary intellectual property, a simple blood test for screening and diagnosing lung cancer at early stages of disease progression.

In addition, the Company undertook a capital raising under a Prospectus to raise \$3,000,000 at \$0.02 per share in accordance with the acquisition transaction and to seek re-compliance for listing on the ASX.

On 17 June 2016 the acquisition transaction was completed with the following issues effected:

- i) 217,003,236 Ordinary Shares issued to the BARD1AG SWAP Vendors (or their respective nominee) in consideration for the acquisition of their respective shares in BARD1AG;
- ii) 217,003,236 Performance Shares issued to the BARD1AG SWAP Vendors (or their respective nominee) in consideration for the acquisition of their respective shares in BARD1AG;
- iii) 12,500,000 Ordinary Shares issued to the Universite de Geneve in full consideration of the Change of Control under the UNIGE Licence Agreement; and
- iv) 150,000,000 Ordinary Shares issued to investors who subscribed in the capital raising

In addition to the above share issues, cash consideration of \$309,421 was provided to certain BARD1AG vendors. As a result of the deemed reverse acquisition under accounting standards as described below, this payment was accounted for as a distribution to owners.

The Company's Shares re-commenced trading on the ASX on 20 June 2016.

Since re-compliance the Company has commenced working to achieve the objectives set out in its Prospectus lodged on 23 March 2016.

1. Reverse acquisition

Under Australian Accounting Standards, BARD1AG was deemed to be the accounting acquirer in this transaction. The acquisition has been accounted for as a share-based payment by which BARD1AG acquired the net assets and listing status of Bard1 Life Sciences Limited.

Accordingly, the consolidated financial statements of the Group have been prepared as a continuation of the business and operations of BARD1AG. As the deemed acquirer, BARD1AG has accounted for the in-substance acquisition of Bard1 Life Sciences Limited from 17 June 2016.

+ See chapter 19 for defined terms

The financial results of the Group are presented in Australian dollars, unless otherwise referenced. The presentation currency of BARD1AG applied in its last set of financial statements was Swiss Francs.

BARD1AG's previous financial year end was 31 December 2015, while Bard1 Life Science Limited's financial year end was 30 June 2016.

The results for the six months ended 30 June 2016 comprise the results of BARD1AG for the six month period and the results of Bard1 Life Sciences Limited subsequent to the completion of the acquisition. The comparative information for the 12 months ended 31 December 2015 is that of BARD1AG as presented in its last set of financial statements, restated for the change in presentation currency as noted above.

The difference between the fair value of the deemed consideration paid by BARD1AG and the fair value of the identifiable net assets of Bard1 Life Sciences Limited of \$2,463,404 was recognised as an expense in the current period income statement.

Consolidated Income Statement
For the six months ended 30 June 2016

	Notes	for the six months ended 30 June 2016 \$	for the year ended 31 December 2015 \$
Employee benefits expense		(13,673)	-
Administration expenses		(114,016)	(85,269)
Listing fee expense on acquisition of Bard1 Life Sciences Limited (formerly Eurogold)		(2,463,404)	-
Loss before income tax		(2,591,093)	(85,269)
Income tax benefit		-	-
Net loss attributable to members of Bard1 Life Sciences Limited		(2,591,093)	(85,269)
Other comprehensive income			
<i>Items that may be subsequently reclassified to operating result</i>			
Foreign currency translation		2,645	(24,584)
Other comprehensive income/(loss) for the period		2,645	(24,584)
Total comprehensive loss for the period, net of tax		(2,588,448)	(109,853)

	for the six months ended 30 June 2016 \$	for the year ended 31 December 2015 \$
Earnings/(loss) per share		
Basic earnings/(loss) per share	(0.01) ⁽¹⁾	(0.0004) ⁽¹⁾
Diluted earnings/(loss) per share	(0.01) ⁽¹⁾	(0.0004) ⁽¹⁾

Based on a weighted average number of shares totalling 241,063,532 (ordinary shares) for the six months ended 30 June 2016 (2015: 217,003,236 ordinary shares based on the issued capital of BARD1AG retrospectively adjusted for the merger ratio). The Company currently has 551,996,585 ordinary shares on issue.

+ See chapter 19 for defined terms

Consolidated Statement of Financial Position
As at 30 June 2016

	Notes	as at 30 June 2016 \$	as at 31 December 2015 \$
Current assets			
Cash and cash equivalents	1	3,097,751	67,164
Receivables		76,412	5,050
Held for trading investments		25,649	-
Total current assets		3,199,812	72,214
Non-current assets			
Property, plant and equipment		8,008	12,261
Financial assets classified as available-for-sale		84,689	-
Total non-current assets		92,697	12,261
Total assets		3,292,509	84,475
Current liabilities			
Trade and other payables		368,977	324,186
Provisions		20,224	-
Convertible notes		69,387	69,902
Total current liabilities		458,588	394,088
Total liabilities		458,588	394,088
Net assets/(liabilities)		2,833,921	(309,613)
Equity			
Issued capital	3	6,370,495	329,092
Distribution reserve		(309,421)	-
Foreign exchange translation reserve		(41,272)	(43,917)
Accumulated losses		(3,185,881)	(594,788)
Total equity/(deficit)		2,833,921	(309,613)

Net tangible assets per security		\$0.005	(\$0.0014)
---	--	----------------	-------------------

+ See chapter 19 for defined terms

Consolidated Cash Flow Statement
For the six months ended 30 June 2016

	Note s	for the six months ended 30 June 2016 \$	for the year ended 31 December 2015 \$
Cash flows from operating activities			
Payments to suppliers & employees		(175,891)	(22,867)
Interest paid		(1,016)	(1,066)
Net cash flows used in operating activities		(176,907)	(23,933)
Cash flows from investing activities			
Net cash acquired on acquisition of subsidiary		925,379	-
Net cash flows from investing activities		925,379	-
Cash flows from financing activities			
Proceeds from issue of shares		3,000,000	-
Convertible notes issued		-	69,902
Distribution to owners		(309,421)	-
Share issue costs		(408,464)	-
Net cash flows from financing activities		2,282,115	69,902
Net increase (decrease) in cash held		3,030,547	45,969
Cash and cash equivalents at beginning of period		67,164	21,195
Cash and cash equivalents at end of period	1	3,097,751	67,164

+ See chapter 19 for defined terms

Consolidated Statement of Changes in Equity

For the six months ended 30 June 2016 and the year ended 31 December 2015

	Issued Capital \$	Foreign Currency Translation reserve \$	Distribution reserve	Accumulated losses \$	Total equity \$
At 31 December 2014	329,092	(19,333)	-	(509,519)	(199,760)
Loss for the year	-	-	-	(85,269)	(85,269)
Other comprehensive income	-	(24,584)	-	-	(24,584)
At 31 December 2015	329,092	(43,917)	-	(594,788)	(309,613)
Loss for the six month period	-	-	-	(2,591,093)	(2,591,093)
Issue of shares, net of costs	6,041,403	-	-	-	6,041,403
Other comprehensive income	-	2,645	-	-	2,645
Distribution to owners	-	-	(309,421)	-	(309,421)
At 30 June 2016	6,370,495	(41,272)	(309,421)	(3,185,881)	2,833,921

+ See chapter 19 for defined terms

1. Reconciliation of cash

Reconciliation of cash at the end of the period (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows:	As at 30 June 2016 \$	As at 31 December 2015 \$
Cash at bank	3,097,751	67,164
Total cash at end of period	3,097,751	67,164

2. Dividends paid and proposed

No dividends have been paid or proposed during the year.

3. Issued capital

	as at 30 June 2016 \$	as at 31 December 2015 \$
Ordinary shares (net of issue costs)	6,370,495	329,092

	Number of shares	\$
At 31 December 2015	217,003,235	329,092
Elimination of all BARD1AG shares on acquisition of Bard1 Life Sciences Limited	(217,003,235)	-
Existing shares of Bard1 Life Sciences Limited	172,493,350	-
Acquisition of BARD1AG	217,003,235	3,199,867
Issue of shares on re-compliance	150,000,000	3,000,000
Issued to University pursuant to agreement	12,500,000	250,000
Less: transaction costs	-	(408,464)
At 30 June 2016	551,996,585	6,370,495

+ See chapter 19 for defined terms

4. Group structure

Companies within the BARD1 Life Sciences Group (all wholly owned) carry out designated activities:

BARD1 Life Sciences limited – Holding Company

BARD1AG – development of the BARD1 Lung Cancer Test

Control was gained over Bard1 Life Sciences Limited on 17 June 2016.

5.

Events subsequent to the balance date

No matters or circumstances have arisen since the end of the financial year which significantly affected or may significantly affect the operations of the Company, the results of those operations or the state of affairs of the Company in future financial years.

6. Annual meeting

(Preliminary final report only)

The annual meeting will be held as follows:

Place	45 Ventnor Avenue, West Perth WA
Date	11 November 2016
Time	TBA
Approximate date the ⁺ annual report will be available	Before 10 October 2016

⁺ See chapter 19 for defined terms

Compliance statement

- 1 This report has been prepared in accordance with AASB Standards, other AASB authoritative pronouncements and Urgent Issues Group Consensus Views or other standards acceptable to ASX.
- 2 This report, and the +accounts upon which the report is based (if separate), use the same accounting policies.
- 3 This report does give a true and fair view of the matters disclosed.
- 4 This report is based on +accounts to which one of the following applies.
(Tick one)

<input type="checkbox"/>	The +accounts have been audited.	<input type="checkbox"/>	The +accounts have been subject to review.
<input checked="" type="checkbox"/>	The +accounts are in the process of being audited or subject to review	<input type="checkbox"/>	The +accounts have <i>not</i> yet been audited or reviewed.

Sign here: Date: 31 August 2016

Print name: Peter Gunzburg
 (Executive Chairman)

+ See chapter 19 for defined terms